H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating on the shares. The company announced that the Phase 2 INVOKE-2 trial, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback